Recombinant Human HLA-A*33:03&B2M Monomer Protein (HEK293)，Avi & His

HLA-A*33:03 and beta-2-microglobulin (B2M) form a crucial component of the major histocompatibility complex (MHC) class I molecules, which play a key role in the immune response by presenting endogenous peptides to CD8+ T cells. The HLA-A*33:03 allele is of particular interest due to its association with various diseases and its role in organ transplantation and autoimmune disorders. Understanding the structural and functional properties of the HLA-A*33:03/B2M monomer is vital for elucidating its mechanism in immune recognition and for developing immunotherapies. Recombinant proteins of HLA-A*33:03 in complex with B2M allow researchers to investigate the peptide binding characteristics, enhance the understanding of T cell recognition, and facilitate the development of vaccines and therapeutics targeting specific diseases. Furthermore, studying this complex can inform the development of predictive models for transplant compatibility and graft rejection, ultimately improving patient outcomes in transplantation settings. The generation of this monomeric form also provides a platform for high-throughput screening of potential therapeutic peptides and can aid in the design of T cell-based immunotherapies. As such, the research on HLA-A*33:03/B2M recombined proteins not only contributes to fundamental immunological knowledge but also has important implications for translational medicine.